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Abstract
Butyltins (BTs), tributyltin (TBT) and dibutyltin (DBT) are organotin compounds that have been 
used in a variety of industrial applications; as a result, these compounds have been found in human 
blood. IL-6 is a pro-inflammatory mediator that is produced by T lymphocytes and monocytes. It 
is responsible for immune response regulation as well as tissue repair and cellular growth. Both 
BTs decrease the ability of human natural killer (NK) cells to destroy tumor cells and alter the 
secretion of pro-inflammatory cytokines tumor necrosis factor alpha (TNFα), interferon gamma 
(IFNγ), and IL-1 beta (β) from human lymphocytes ex vivo. Here, we show that BTs alter the 
secretion of IL-6 from increasingly reconstituted preparations of human immune cells. IL-6 
secretion was examined after 24h, 48h, or 6 day exposures to TBT and DBT in highly enriched 
human NK cells, monocyte-depleted (MD) peripheral blood mononuclear cells (MD-PBMCs), 
PBMCs, granulocytes, and a preparation combining both PBMCs and granulocytes (PBMCs
+granulocytes). The results indicated that both BTs altered IL-6 secretion from all cell 
preparations. Significant decreases of IL-6 secretion were seen at the highest concentration of TBT 
(200 nM) and DBT (5–2.5 µM) while the lower concentrations of DBT (0.05 and 0.1 µM) caused 
elevation of IL-6 secretion. The data indicates that BT-induced alterations of IL-6 secretion from 
immune cells may be a significant consequence of BT exposures that may potentially affect 
immune competence.
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Introduction
Interleukin 6 (IL-6) is a glycosylated protein (22–27 kDA) (Kishimoto, 1989), and is mainly 
produced by monocytes/macrophages, fibroblasts, and vascular endothelial cells (Akira et 
al., 1993). It is also produced by T and NK lymphocytes (Li and He, 2006; Hall et al., 2010) 
and granulocytes (Riedemann et al., 2004; Zimmermann et al., 2014; 2016). MAP kinase 
and NFκB signaling pathways are utilized in the regulation of its production (Gaestel et al., 
2009). IL-6 belongs to a family of cytokines that consists of IL-11, leukemia inhibitory 
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factor, oncostatin M, ciliary neurotropic factor, cardiotrophin-1, cardiotrophin-like related 
cytokine, neuropoietin and IL-27. The similarity with IL-6 and this cytokine family is the 
utilization of the transmembrane glycoprotein gp130 in its signal transduction pathway 
(Gearing et al., 1992; Heinrich et al., 2003; Hirano et al., 1994; Ip et al., 1992; Liu et al., 
1992; Pennica et al., 1995; Yin et al., 1993). Activation of JAK/STAT and MAPK pathways 
can occur through the activation of a membrane-bound IL-6 receptor (IL-6R) and gp130 
expressed on the cell surface (termed classic signaling) (Heinrich et al., 2003; Scheller et al., 
2006). Cells that express IL-6R on the cell surface include macrophages, neutrophils, some 
T-cells, and hepatocytes (Scheller et al., 2011). Those same pathways can also be activated 
by a soluble IL-6R in conjunction with gp130 in cells that have no endogenous IL-6R 
expressed on their surface (termed trans-signaling) (Scheller et al., 2006; Scheller et al., 
2011; Rose-John, 2012). Trans-signaling has been demonstrated in chronic inflammatory 
diseases such as colon cancer, colitis, and peritonitis (Atreya et al., 2000; Hurst et al., 2001). 
IL-6 regulates endometrial tissue growth, bone formation, and hormone synthesis (Naitoh et 
al., 1988; Spangelo et al., 1989). Elevation of IL-6 can be seen in inflammatory diseases 
such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and Crohn’s disease 
(Gabay, 2006). High IL-6 levels have been shown in patients with carcinomas such as breast, 
lung, and lymphoma (Hong et al., 2007). Elevation of IL-6 levels correlates with tumor 
progression (Culig et al., 2005; Nilsson et al., 2005).
Butyltins (BTs) are man-made organotins that include tributyltin (TBT) and its metabolites 
dibutyltin (DBT) and monobutyltin (MBT). TBT and DBT have been used in a range of 
industrial and consumer applications, thus leading to environmental contamination 
(Kimbrough, 1976; Tanabe et al., 1998; Roper, 1992; Gipperth, 2009; Takahashi et al., 1999; 
Kannan et al., 1995; Forsyth et al., 1992; Forsyth and Jay, 1997; Sadiki et al., 1996). TBT 
has been used for wood preservation, slime control in paper mills, and antifungal agent in 
industrial cooling water systems and breweries (Antizar-Ladislao, 2008; Gipperth, 2009; 
Kannan et al., 1995; Kannan et al., 1999). It has contaminated the marine and fresh water 
environment due to antifouling paint usage on boats and ships. Although TBT use as a 
marine antifouling agent was restricted in the United States in the 1980s (Loganathan et al., 
2001; Loganathan, 2016) and banned by the International Convention on the Control of 
Harmful Antifouling Systems on Ships in 2008 (Gipperth, 2009), it is still contaminating the 
environment due to its chemical stability (Gipperth, 2009) and use by those who do not 
acknowledge the ban. As a result, TBT has been found in human blood samples (ranging as 
high as 261 nM) and other tissues through the consumption of fish and other foods (Antizar-
Ladislao, 2008; Kannan et al., 1995; Kannan et al., 1999; Whalen et al., 1999). It is also 
found in some household goods such as siliconized-paper baking parchments and shower 
curtains (Yamada et al., 1993). Mammals with TBT exposure show increased incidences of 
tumors (Wester et al., 1990).
DBT is used as a stabilizer in polyvinyl chloride (PVC) plastics such as pipes that distribute 
drinking water (Forsyth et al., 1992; Forsyth and Jay, 1997; Sadiki et al., 1996) and some 
plastic food containers (Nakashima et al., 1990; Yamada et al., 1993). DBT can leach from 
PVC plastics (Fent, 1996); as a result, it has been found in water samples (Sadiki and 
Williams, 1999). DBT is also used as de-worming agent in certain poultry and is found in 
some poultry products (Epstein et al., 1991). Due to these routes of exposure, DBT has been 
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found in human blood samples ranging as high as 300 nM (Kannan et al., 1999; Whalen et 
al., 1999).
Both BTs decrease the ability of human NK cells to destroy tumor cells with accompanying 
decreases in cytotoxic and cell surface protein expression (Dudimah et al., 2007a; Dudimah 
et al., 2007b; Thomas et al., 2004; Whalen et al., 2002). In addition, both TBT and DBT 
inhibit and stimulate the secretion of tumor necrosis factor alpha (TNFα), interferon gamma 
(IFNγ), and IL-1β from human lymphocytes (depending on the exposure concentration) 
(Hurt et al., 2013; Lawrence et al., 2015; Brown and Whalen, 2015; Brown et. al, 2017). 
TBT is more potent than DBT in causing these immunomodulatory alterations. The 
importance of introducing TBT and DBT as stress inducers to the cell environment is to 
understand whether exposure to BTs disrupt the secretion interleukin 6 (IL-6). Based on the 
effect of both BTs on TNFα, IFNγ, and IL-1β (Hurt et al., 2013; Lawrence et al., 2015; 
Brown and Whalen, 2015; Brown et. al, 2017), we hypothesize that exposure to TBT and 
DBT will alter the ability of human lymphocytes to secrete IL-6.
In this study, increasingly complex preparations of immune cells were examined for the 
effects of BT exposures on the secretion of IL-6. The preparations studied included: human 
NK cells, human monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCs) 
(MD-PBMCs), PBMCs, PBMCs combined with granulocytes (PBMCs+granulocytes), and 
granulocytes. The use of increasingly reconstituted immune cell preparations allowed us to 
investigate the influence that various immune cell types may have on the ability of BTs to 
induce alteration in secretion of IL-6 which gives a better account for physiological 
circumstances. This work is significant because any disruption of the cytokines may indicate 
that TBT and DBT exposures may potentially affect immune competence as well as diseases 
that are influenced by increased levels of this pro-inflammatory cytokine as mentioned 
above.
Materials and Methods
Preparation of PBMCs, MD- PBMCs, and Granulocytes
PBMCs were isolated from Leukocyte filters (PALL- RCPL or RC2D) obtained from the 
Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. 
Leukocytes were retrieved from the filters by back-flushing them with an elution medium 
(sterile PBS containing 5 mM disodium EDTA and 2.5% [w/v] sucrose) and collecting the 
eluent. The eluent was layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200g 
for 30–50 min. Granulocytes and red blood cells pelleted at the bottom of the tube while the 
PBMCs floated on the Ficoll-Hypaque. Mononuclear cells were collected and washed with 
PBS (500g, 10min). Following washing, the cells were layered on bovine calf serum for 
platelet removal. The cells were then suspended in RPMI-1640 complete medium which 
consisted of RPMI-1640 supplemented with 10% heat-inactivated BCS, 2 mM L-glutamine 
and 50 U penicillin G with 50 µg streptomycin/mL. This preparation constituted PBMCs. 
PBMCs are composed of 70–90% lymphocytes and 10–30% monocytes. Monocyte-depleted 
PBMCs (10–20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+) 
were prepared by incubating the cells in glass Petri dishes (150 × 15 mm) at 37 °C and 
air/CO2, 19:1 for 1.5 h. This cell preparation is referred to as MD-PBMCS cells. 
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Granulocytes were isolated with the removal of mononuclear and red blood cells as 
described in Kuijpers et al., 2013. Granulocytes were collected and washed with PBS (2500 
rpm, 15min). Red blood cells were lysed with NH4CL isotonic solution (155mM NH4Cl, 
10mM KHCO3, 0.1 mM EDTA) for 10 min. Cells were then washed with PBS and 
centrifuged at 800g for 10 min. This preparation was greater than 90% granulocytes. The 
cells were then suspended in RPMI-1640 complete medium supplemented with 10% heat-
inactivated BCS, 2 mM L-glutamine and 50 U penicillin G with 50 µg streptomycin/mL.
Preparation of NK cells
NK cells were prepared from buffy coats (from healthy adult donors) purchased from Key 
Biologics, LLC (Memphis, TN). Highly purified NK cells were prepared using a rosetting 
procedure. RosetteSep human NK cell enrichment antibody cocktail (0.6–0.8 mL) (StemCell 
Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of buffy coat. The 
mixture was incubated for 20 min at room temperature (~ 25° C). Approximately 8 mL of 
the mixture was layered onto 4 mL of Ficoll-Hypaque (1.077 g/mL) (MP Biomedicals, 
Irvine, CA) and centrifuged at 1200 g for 30–50 min. NK cells were collected and washed 
twice with phosphate buffered saline (PBS) pH 7.2 and stored in complete media 
(RPMI-1640 supplemented with 10% heat-inactivated bovine calf serum (BCS), 2 mM L-
glutamine and 50 U penicillin G with 50 µg streptomycin/ml) at 1 million cells/mL at 37 °C 
and air/CO2, 19:1. The preparation was greater than 85% NK cells.
Chemical Preparation
The organotin compounds tributyltin chloride (TBT) and dibutyltin dicholoride (DBT) were 
purchased from Sigma-Aldrich (96%) (St. Louis, MO). A DBT stock solution was prepared 
by dissolving DBT in dimethylsulfoxide (DMSO). Desired concentrations of DBT were 
prepared by dilution of the stock into cell culture media. The final concentration of DMSO 
for DBT exposures did not exceed 0.01%. Appropriate DMSO controls were run. Desired 
concentrations of TBT were prepared by dilution of the stock into cell culture media. TBT 
was a neat standard, dissolved initially in deionized water to give a 1 mM solution.
Cell Treatments
NK cells, MD-PBMCs, PBMCs, granulocytes (at a concentration of 1.5 million cells/ mL), 
or PBMCs+granulocytes (at a concentration of 1.5 million PBMCs/mL + 1.5 million 
granulocytes/mL) were treated with TBT at concentrations of 2.5–200 nM TBT for 24 h, 48 
h, or 6 days. Following the incubations, the cells were pelleted and supernatants were 
collected and stored at −70° C until assaying for IL-6.
NK cells, MD-PBMCs, PBMCs, granulocytes (at a concentration of 1.5 million cells/ mL), 
or PBMCs+granulocytes (at a concentration of 1.5 million PBMCs/mL + 1.5 million 
granulocytes/mL) were treated with DBT at concentrations of 0.05–5 µM for 24 h, 48 h, or 6 
days. Following the incubations, the cells were pelleted and supernatants were collected and 
stored at −70° C until assaying for IL-6.
TNFα and IL-1β were tested for their ability to stimulate secretion of IL-6. MD-PBMCs 
were treated with TNFα or IL-1β (10,000 pg/mL, 1000 pg/mL and 100 pg/mL) for 24 h. 
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Following the incubations supernatants were collected and stored as described above until 
being tested for IL-6 secretion.
Antibodies to TNF, IL-1β, and an isotype control (BD-Pharmingen, San Diego, CA) were 
added to PBMCs 1 h prior to exposing the cells to DBT (0.25–0.05 µM) for 24 h. Following 
the incubations, supernatants were collected and stored as described above until assaying for 
IL-6.
Cell Viability
Cell viability was assessed at the beginning and end of each exposure period. Viability was 
determined using the trypan blue exclusion method. Briefly, cells were mixed with trypan 
blue and counted using a hemocytometer. The total number of cells and the total number of 
live cells were determined for both control and treated cells to determine the percent viable 
cells.
IL-6 Secretion Assay
IL-6 levels were measured using the BD OptEIA™ Human IL-6 enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). Briefly, a 96-well 
micro well plate, designed for ELISA (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for IL-6 diluted in coating buffer. The plate was incubated with the capture 
antibody overnight at 4°C. After incubation, the capture antibody was removed by washing 
the plate three times with wash buffer (PBS and 0.05% Tween-20). Assay diluent (PBS and 
bovine calf serum) was added to each well (blocking non-specific binding) and incubated at 
room temperature for 1h. The assay diluent was removed by washing the plate three times, 
and the cell supernatants and IL-6 standards were added to the coated plated and incubated 
for 2 h at room temperature. Following this incubation, the plate was thoroughly washed five 
times and then incubated for 1h with a detection antibody to IL-6 which was conjugated 
with horseradish peroxidase. The excess detection antibody was removed by washing seven 
times and a substrate solution was added for 30 min at room temperature to produce a 
colored product. The incubation with the substrate was ended by addition of acid and the 
absorbance was measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 plate 
reader (Fisher Scientific).
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s t 
test, a p value of less than 0.05 was considered significant.
Results
Viability of NK cells, MD-PBMCs, PBMCs, PBMCs+ Granulocytes, and Granulocytes 
exposed to TBT
Table 1 shows the effects of TBT exposures (2.5–200 nM) on the viability of highly purified 
NK cells, MD-PBMCs, PBMCs, PBMCs+granulocytes, and granulocytes. Exposure of NK 
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cells to 2.5–100 nM TBT had no effect on their viability as compared to the control after 24 
h length of exposure. A slight decrease in NK cell viability was noticed at the highest 
concentration of TBT (200 nM). Exposure to these same concentrations for 48 h caused 
some decrease (about 20%) only at the highest concentration of TBT while the remaining 
concentrations showed no decrease in viability compared to control cells. NK cells exposed 
to 2.5–50 nM TBT for 6 days showed no change in viability as compared to the control. A 
significant reduction in viability of 50% was seen with 200 nM TBT exposures. MD-
PBMCs showed a very slight decrease in viability with exposure to 200 nM TBT while 
PBMCs showed significant decreases at 100 nM (about 18%) and 200 nM (about 38%) for 
24 h. Both MD-PBMCs and PBMCs showed significant decreases in viability at the highest 
concentration after 48 h exposure. Significant decreases were also seen after 6 days for MD-
PBMCs and PBMCs for TBT concentrations of 100, and 200 nM. Exposure of PBMCs
+granulocytes to TBT did not significantly decrease viability compared to control cells after 
any length of incubation. Exposure to 200 nM TBT for 48 h and 6 days significantly 
diminished the viability of granulocytes.
Viability of NK cells, MD-PBMCs, PBMCs, PBMCs+ Granulocytes, and Granulocytes 
exposed to DBT
Table 2 shows the effects of DBT exposures (0.05–5 µM) on the viability of the various 
immune cell preparations. NK cells exposed to DBT for 48 h showed significant reductions 
in viability (around 35%) at 2.5 and 5 µM. No statistically significant change in viability as 
compared to control cells was seen after 6 days of exposure. MD-PBMCs and PBMCs both 
showed a significant decrease in viability with exposure to 5 µM DBT for 24 h. The viability 
of MD-PBMCs at 48 h was significantly reduced by exposure to 1 (15%), 2.5 (40%), and 5 
µM (41%) DBT. After 6 days of exposure 0.5 µM DBT also caused significant reductions in 
viability of MD-PBMCs. The viability of PBMCs+granulocytes and granulocytes alone was 
not significantly affected by exposure to DBT.
Effects of TBT Exposure on Secretion of IL-6 by NK cells
Table 3 shows the effects of TBT (0, 2.5, 5, 10, 25, 50, 100, and 200 nM) exposure on IL-6 
secretion from NK cells. Cells from 4 different donors were exposed to TBT for 24 h, 48 h, 
and 6 days (KB=Key Biologic buffy coat). All donors showed significant decreases in IL-6 
secretion when exposed to 100 and 200 nM TBT at 24 h, 48 h, and 6 days. Figure 1A shows 
the decreases from a representative experiment (KB169).
Effects of TBT Exposure on Secretion of IL-6 by MD-PBMCs
Table 4 summarizes the effects of exposing MD-PBMCs from 4 individual donors to TBT 
on IL-6 secretion (F=filter obtained from the Red Cross). Significant decreases in IL-6 
secretion were seen in cells from all donors at 200 nM TBT. Additionally, cells from 3 of 4 
donors showed an increase in secretion after exposure for 24 h, 48 h, or 6 days at one or 
more concentration of TBT. The maximum increase of IL-6 in cells from one donor was 
1.34 fold (F137 at 2.5 nM after 48 h). Figure 1B shows the effects of TBT exposures for an 
individual donor (F156).
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Effects of TBT Exposure on Secretion of IL-6 by PBMCs
The effects of exposures to TBT on secretion of IL-6 from PBMCs from 4 donors are shown 
in Table 5a. All donors showed significant decreases in IL-6 secretion after 24 h and 6 days 
of exposure to 200 nM TBT. Cells from each of the donors showed increased secretion of 
IL-6 at one or more TBT exposure after 24 and 48 h. The range of maximum increases after 
24 h was 1.1 fold (F252, 2.5 nM), 1.4 fold (F257, 50 nM), 1.4 fold (F261, 2.5 nM), and 2.4 
fold (F264, 2.5 nM). The effects of TBT exposures for a representative experiment are 
shown in Figure 1C (F261).
Effects of TBT Exposure on Secretion of IL-6 by PBMCs + Granulocytes
Effects of exposing PBMCs+granulocytes (prepared from the same 4 donors as PBMCs) to 
TBT on IL-6 secretion are shown in Table 5b. Cells from 3 of the 4 donors showed a 
significant decrease in IL-6 secretion at 200 nM TBT after either 24 h or 48 h of exposure, 
with 3 of the 4 donors showing a significant decrease at this concentration after 48 h. As 
with PBMCs alone, the combination of PBMCs+granulocytes also showed TBT-induced 
increases in IL-6 secretion in cells from all donors at each length of exposure. However, 
TBT-induced increases were of the greatest magnitude after 6 days (all donors) (11.8 fold 
for F252, 6.8 fold for F257, 7.5 fold for F261, 18.4 fold for F264). The increases are shown 
from an individual donor in Figure 1D (F261).
Effects of TBT Exposure on Secretion of IL-6 by Granulocytes
The effects of exposures to TBT on secretion of IL-6 were examined in granulocytes 
prepared from the same 4 donors as were PBMCs (results shown in Table 5c). All donors 
showed significant decreases of IL-6 secretion at 200 nM TBT after 24 h length of exposure. 
Significant increases in IL-6 secretion were seen at TBT levels ranging from 2.5–100 nM 
after 24 h and TBT levels ranging from 5–50 nM after 48 h for all donors. The fold increases 
seen after 48 h exposures to 5 nM TBT were 273 (F252), 8 (F257), 3.5 (F261), and 1.1 
(F264). Minimal IL-6 secretion was noted after 6 days of exposure. However, 2.5 nM TBT 
induced substantial increases in the granulocytes from each of the donors after 6 days of 
exposure (2.8 fold for F252, 9.6 fold for F257, 4.8 fold for F261, and 3.5 fold for F264). 
Figure 1E shows the effects of TBT exposures from an individual donor (F261).
Effects of DBT Exposure on Secretion of IL-6 by NK cells
The effects of DBT (0, 0.05, 0.1, 0.25, 0.05, 1, 2.5 and 5 µM) exposures on IL-6 secretion 
from NK cells are shown in Table 6. Cells from 3 different donors were exposed to DBT for 
the same lengths of exposure as were used in the TBT studies. All donors showed significant 
decreases in IL-6 secretion when exposed to 0.5, 1, 2.5, and 5 µM DBT at all lengths of 
exposure. Additionally, all donors showed increased IL-6 secretion with exposures to one or 
more concentration of DBT in the range of 0.05 to 0.25 µM DBT after 24 h and/or 48 h 
exposures. The increases were rather modest ranging from 1.2–1.5 fold. Figure 2A shows 
the effects of DBT exposures at each length of exposure for a representative experiment 
(KB169).
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Effects of DBT Exposure on Secretion of IL-6 by MD-PBMCs
Table 7 shows the effects of exposing MD-PBMCs to DBT on IL-6 secretion. Cells from 5 
different donors were exposed to DBT. All donors showed significant decreases at 2.5 and 5 
µM DBT at all lengths of exposure. Additionally, all donors showed DBT-induced increases 
in secretion at one or more length of exposure with concentrations of DBT in the range of 
0.5–0.25 µM. The effects of DBT exposures for a representative experiment are shown in 
Figure 2B (F152).
Effects of DBT Exposure on Secretion of IL-6 by PBMCs
Table 8a summarizes the effects of exposing PBMCs from 4 individual donors to DBT on 
IL-6 secretion. Significant decreases were seen at the 5 µM concentration in cells from each 
of the donors at all lengths of exposure. Cells from the vast majority of donors also showed 
very significant decreases with exposures to 1 and 2.5 µM DBT. Significant increases were 
seen at lower concentrations of DBT (0.05 to 0.5 µM) in cells from all donors after 48 h and 
6 day exposures. Cells from 3 of the 4 donors also showed increases after 24 h of exposure. 
Figure 2C shows the effects of DBT exposures from an individual donor (F285).
Effects of DBT Exposure on Secretion of IL-6 by PBMCs + Granulocytes
Effects of exposing PBMCs+granulocytes (prepared from the same 4 donors as PBMCs) to 
DBT on IL-6 secretion are shown in Table 8b. After 24 and 48 h of exposure, all donors 
showed significant decreases in IL-6 secretion at 2.5 and 5 µM DBT. All lengths of exposure 
displayed significant increases at 0.25 µM DBT for all donors. Figure 2D shows the effects 
of TBT exposures for an individual donor (F285).
Effects of DBT Exposure on Secretion of IL-6 by Granulocytes
The effects of exposures to DBT on secretion of IL-6 were examined in granulocytes 
prepared from the same 4 donors as were PBMCs (results shown in Table 8c). Cells from all 
donors showed significant decreases in IL-6 secretion at 2.5 and 5 µM DBT after 24 h and 
48 h exposures. However, significant increases were seen at DBT concentrations of 0.05, 
0.1, and 0.5 µM for 3 of the 4 donors after 24 h of exposure. Cells from the fourth donor 
(F294) showed a small but significant increase in IL-6 secretion after 48 h. Cells from 3 of 
the 4 donors continued to show DBT-stimulated increases in IL-6 secretion after 6 days 
while the secretion from control cells was nonexistent or very low. Cells from the fourth 
donor (F294) showed no IL-6 secretion under any condition after 6 days. Figure 2E shows 
the effects of TBT exposures for an individual donor (F285).
Ability of TNFα and IL-1β to stimulate IL-6 secretion
The effects of TNFα to elicit secretion of IL-6 from MD-PBMCs were examined. Figure 3A 
shows that incubation of MD-PBMCs for 24 h with 10,000 pg/mL of TNFα increased the 
secretion of IL-6 by 2.5 fold. When the amount of TNFα was 1000 pg/mL the fold increase 
in IL-6 secretion was 1.3 fold. When MD-PBMCs were treated with 1000 pg/mL of IL-1β 
for 24 h there was a 2 fold increase in IL-6 secretion. A 24 h exposure of the cells to 100 pg/ 
mL IL-1β caused a 1.4 fold increase (Figure 3B). Antibodies to TNFα (TAb), IL-1β (IAb) 
and an isotype control (CAb) were added to PBMCs prior to exposure to DBT in order to 
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see if DBT-induced secretion of either of these cytokines was responsible for a portion of the 
increase seen with BT exposure. As seen in Figure 3C, there was no decrease in DBT-
induced elevation of IL-6 when either TNFα or isotype control antibodies were present. 
There was a very slight decrease in DBT-induced IL-6 secretion when IL-1β antibody was 
present. However, when both TNF and IL-1β antibodies were present there was no decrease.
Discussion
BTs, TBT and DBT, have been used in a variety of industrial applications such as 
antifouling paints (TBT) (Gipperth, 2009) and stabilizer of plastics (DBT) (Forsyth et al., 
1992; Forsyth and Jay, 1997; Sadiki et al., 1996). Levels of BTs have been found as high as 
261 nM TBT (Kannan et al., 1995; Whalen et al., 1999) and 0.3 µM DBT in human blood 
(Kannan et al., 1999; Whalen et al., 1999). Both BTs decrease the ability of human NK cells 
to destroy tumor cells (Dudimah et al., 2007a; Dudimah et al., 2007b; Thomas et al., 2004; 
Whalen et al., 2002) and alter the secretion of TNFα, IFNγ, and IL-1β from immune cells 
(Brown and Whalen, 2015; Brown et al., 2017; Hurt et al., 2013; Lawrence et al., 2015). 
IL-6 is necessary for normal immune functions (Naitoh et al., 1988; Spangelo et al., 1989); 
however, elevation of this cytokine can lead to inflammatory diseases and carcinomas 
(Gabay, 2006; Hong et al., 2007). We investigated whether BTs alter the secretion of IL-6 
from immune cells in an ex vivo human model. Increasingly complex cell preparations were 
used (NK cells, MD-PBMCs, PBMCs, PBMC+granulocytes, and granulocytes) to 
investigate whether certain cell types or combinations of cell types were more susceptible to 
alterations of IL-6 secretion by either TBT or DBT.
TBT induced both increases and decreases in IL-6 secretion from human immune cells. The 
highest concentration of TBT (200 nM) decreased IL-6 secretion from all cell preparations 
at one or more length of incubation. These decreases were seen in NK cells and monocyte-
depleted (MD)-PBMCs (predominantly T and NK lymphocytes) from all donors after a 24 h 
exposure to TBT. However, in PBMCs, PBMCs+granulocytes, and granulocytes alone the 
length of exposure at which a decrease was seen with exposure to 200 nM TBT varied 
among cells from different donors. This indicated that the presence of monocytes and 
granulocytes changed the effectiveness of 200 nM TBT in inhibiting IL-6 secretion. 
Increases in IL-6 secretion seen with exposures to TBT were consistently seen in MD-
PBMCs and PBMCs. However, while TBT induced increases in 3 of 4 donors in NK cells, 
the length of exposure and concentration of TBT at which the increases occurred varied 
from donor to donor.
When monocytes and granulocytes were present the TBT-induced decreases in IL-6 became 
less consistent but TBT-induced increases were seen in all donors at all lengths of exposure. 
While PMBCs and granulocytes prepared from every donor showed TBT-induced increases 
in IL-6 secretion, it was the granulocytes that showed the greatest sensitivity to TBT. The 
baseline secretion of IL-6 is much lower in granulocytes than in PBMCs. For example, 
PBMCs from donor F257 had a baseline secretion of 123,182 pg/mL at 24 h and a maximal 
TBT-induced increase in IL-6 secretion of 1.4 fold (50 nM). Granulocytes from this same 
donor had a baseline secretion of 137 pg/mL with an increase of 3.7 fold in IL-6 secretion 
induced by 2.5 nM TBT. This same pattern was seen across donors. Thus, results of this 
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study indicate that higher concentrations of TBT are most effective at decreasing IL-6 
secretion in cell preparations that do not contain monocytes or granulocytes. Conversely, 
concentrations of TBT of 100 nM and below are most effective at elevating IL-6 secretion 
when monocytes and granulocytes are present. Granulocytes are the most sensitive cell type 
to TBT-induced elevation of IL-6 secretion. As neutrophils are the most abundant white 
blood cell, the ability of TBT to induce very large increases in their normally low secretion 
of the important pro-inflammatory cytokine, IL-6, could lead to very significant disruption 
of the immune response leading to unwarranted inflammation.
DBT also altered IL-6 secretion from each of the immune cell preparations that were 
examined. The two highest concentrations of DBT (5 and 2.5 µM) induced a nearly 
complete blockage of IL-6 secretion from NK cells, MD-PBMCs, PBMCs, PBMCs
+granulocytes, and granulocytes. These DBT concentrations caused some decrease in 
viability, but the decrease in IL-6 secretion was far greater than any decreases seen in 
viability at any of the time points or concentrations. Lower concentrations of DBT (ranging 
from 0.05 to 0.5 µM) induced elevation of IL-6 secretion in NK cells, MD-PBMCs, PBMCs, 
PBMCs+granulocytes and granulocytes at one or more length of incubation. As was seen 
with TBT, the length of exposure and the concentration of DBT at which the increases in 
IL-6 occurred in NK cells varied from donor to donor. Past studies have shown that DBT (at 
lower concentrations) is able to increase both IL-1β and TNFα secretion from human 
immune cell preparations that contain T-lymphocytes and monocytes (Hurt et al., 2013; 
Brown et al., 2017). Again, similar to TBT, the increases induced by DBT exposures 
occurred most consistently when monocytes were present. As mentioned above, granulocyte 
secretion of IL-6 was more sensitive to TBT-induced elevation than were other cell types. 
This was not the case for DBT. For instance, PBMCs from donor F294 showed an increase 
in IL-6 secretion of 2 fold when exposed to 0.25 µM DBT for 24 h. PBMCs+granulocytes 
from this same donor showed only a 1.2 fold increase under the same conditions and 
granulocytes alone showed no increase. Thus, unlike the results seen with TBT, DBT 
appears to be most effective at increasing IL-6 elevation from monocytes rather than 
granulocytes.
It is known that other cytokines such as IL-1β and TNFα are able to stimulate IL-6 
production in a variety of cells including skeletal muscle cells (Luo et al., 2003; McGee et 
al., 1995; Ostrowski et al., 1998b; Ostrowski et al., 1998a; Pedersen et al., 2001; Tilg et al., 
1997; Tosato and Jones, 1990). Monocyte production of IL-6 is stimulated by IL-1β (Tosato 
and Jones, 1990). Thus, we investigated whether BT-stimulated T lymphocyte (or monocyte) 
production of one of these cytokines may be responsible for the increase in IL-6. Previously, 
we have shown that TBT and DBT are able to induce elevations in MD-PBMC production of 
both TNFα and IL-1β (Hurt et al., 2013; Lawrence et al., 2015; Brown and Whalen 2015). 
Thus, either TNFα and/or IL-1β secreted by monocytes or T lymphocytes in response to 
either TBT or DBT could explain, at least in part, the BT-induced increases in IL-6 secretion 
from immune cells seen in this study. Here we showed that when cells were treated with 
either TNFα or IL-1β (“addition experiments”) there was a significant increase in IL-6 
production by these cells, IL-1β was more effective than TNFα in its ability to stimulate this 
increase. However, there was no major loss of BT-induced increases in IL-6 when antibodies 
to IL-1β or TNFα were added prior to exposure to DBT. Thus, while the “addition 
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experiments” suggest that IL-1β and/ or TNFα might be in part responsible for the increases 
in IL-6 secretion stimulated by BTs, the results of experiments using antibodies to diminish 
levels of DBT-induced IL-1β or TNFα did not corroborate those results. However, there are 
complications in the antibody experiments that could obscure the interpretation of the 
results. For instance, the incubation conditions allow for the cells to become closely packed 
(due to settling in the tube) and this might limit access of the antibody to areas where high 
concentrations of secreted IL-1β and TNFα would occur. Thus, the competition between 
these cytokines’ receptors on the cell surface and the antibody for DBT-generated IL-1β and 
TNFα might greatly favor the receptors. Additionally, it has been shown that the receptors 
for TNF generally have significantly higher affinities for the cytokine than do many 
antibodies (Lang et al., 2016; Song et al., 2008).
In addition to their effect on cytokine secretion shown here and in previous studies (Hurt et 
al., 2013; Brown and Whalen, 2015; Lawrence et al., 2015; Brown et al., 2017), both TBT 
and DBT have been shown to induce apoptosis of thymocytes in vitro (Gennari et al., 1997) 
and degeneration of the thymus (maturation site of T-cells) in rats (Snoeij et al., 1988). 
Comparison of TBT and DBT effects on IL-6 secretion in NK cells from the same donor at 
the same concentrations (50 and 100 nM) showed that TBT inhibited IL-6 secretion from 
NK cells by 97.7% at 100 nM whereas DBT inhibited secretion by 9%. When the relative 
effectiveness of TBT and DBT were compared in MD-PBMCs from the same donor, we 
found that TBT inhibited IL-6 secretion at 50 or 100 nM while DBT either had no effect or 
stimulated IL-6 secretion at these same concentrations. The greater effectiveness of TBT 
over DBT has been seen previously when comparing the effects of TBT and DBT on IL-1β 
secretion (Brown et al., 2017). Taken together, these comparisons indicate that DBT may be 
generally less effective at inducing an increase in both IL-6 and IL-1β secretion than is TBT. 
This may be due to the fact that DBT is less hydrophobic than TBT due to the loss of the 
third butyl group (Laughlin et al., 1986; Harper, 2005) and is less able to enter the cell to 
bind to intracellular targets (such as MAPKs (Brown et al., 2017) that appear to be involved 
in the compound-induced increases in IL-1β secretion which appear to be at least in part 
responsible for inducing increases in IL-6 as discussed above. This study also suggests that 
DBT has a lower affinity for those intracellular components that are responsible for causing 
decreased IL-6 secretion and thus is somewhat less effective at inducing that effect.
A previous study demonstrated that DBT alters IL-1β secretion from increasingly 
reconstituted preparations of human immune cells (Brown et al., 2017). As was seen with 
IL-6 secretion in the current study, higher concentrations of DBT (5 and 2.5 µM) decreased 
the secretion of IL-1β, while lower concentrations (0.1 and 0.05 µM) increased the secretion 
of IL-1β. However, in contrast to the effects of DBT on IL-6 secretion, the secretion of 
IL-1β was increased when NK cells were exposed to lower concentrations of DBT for at 
each length of incubation. As mentioned above, there was no consistent increase in secretion 
of IL-6 by NK cells in response to DBT exposures. Additionally, the greater sensitivity of 
granulocytes to TBT-induced increases in IL-6 secretion that was seen in the current study 
did not occur when looking at granulocyte secretion of IL-1β (Brown and Whalen, 2015).
These results suggest that TBT and DBT-induced alterations of IL-6 secretion as well as 
other pro-inflammatory cytokines from immune cells may potentially affect immune 
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function and cancer invasiveness. Monobutyltin (MBT), which can be a breakdown product 
of both TBT and DBT, was not examined in this study as it showed very limited effects on 
immune cell function in previous studies (Whalen et al., 1999) and no effects at levels 
measured in human blood (Kannan et al., 1999). The levels of TBT and DBT found in 
human blood samples are in the range of TBT and DBT concentrations that elevated IL-6 
levels. The fact that both of these compounds are able to alter IL-6 secretion suggests that at 
higher concentrations they may decrease immune competency. Lower concentrations of 
either TBT or DBT may lead to increased levels of IL-6 which could produce chronic 
inflammation. Increased inflammation in the absence of a microorganism is referred to as 
“sterile inflammation” (Chen and Nunez, 2010). Compound such as TBT and DBT may 
have the capacity to induce sterile inflammation by their ability to increase the production of 
pro-inflammatory cytokines such as IL-6 and other pro-inflammatory cytokines (Hurt et al., 
2013; Brown and Whalen, 2015; Lawrence et al., 2015; Brown et al., 2017). The results of 
this study, as well as previous studies, indicate that these two compounds may be more of a 
problem in terms of causing chronic inflammation rather than loss of immune competence in 
exposed individuals due to the fact that a large percentage of the individuals whose blood 
levels were measured had levels in the range where effects on IL-6 secretion were seen ex 
vivo (Whalen et al., 1999; Kannan et al., 1999). Interestingly, a rise in Rheumatoid arthritis 
(Myasoedova et al., 2010) (one of the several diseases where Il-6 is elevated) has been noted 
over the period of 1955–2007 as the use of compounds such as TBT and DBT with their 
concomitant contamination of the human system has been increasing.
In summary, both TBT and DBT are able to alter the secretion of IL-6 in a range of human 
immune cell preparations. Both compounds decrease the secretion of IL-6 at the highest 
concentration (TBT=200 nM, DBT= 5 and 2.5 µM)) from NK cells, MD-PBMCs, PBMCs, 
PBMCs+granulocytes, and granulocytes alone. TBT (50–2.5 nM) and DBT (0.5–0.05 µM) 
are also able to increase the secretion of IL-6 at lower exposure levels and this is effect is 
most consistent when either T lymphocytes or monocytes are present. The cell type that is 
most sensitive to TBT-induced increases in IL-6 are granulocytes. Cell preparations 
containing T lymphocytes and/or monocytes were the most sensitive to DBT-induced 
elevation of IL-6 secretion.
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Effects of 24 h, 48 h and 6 day exposures to TBT on IL-6 secretion from highly purified 
human NK cells, monocyte-depleted PBMCs, PBMCs, PBMCs plus granulocytes, and 
granulocytes in individual donors. A) NK cells exposed to 0–200 nM TBT (donor KB169). 
B) Monocyte-depleted PBMCs exposed to 0–200 nM TBT (donor F156). C) PBMCs 
exposed to 0–200 nM TBT (donor F261). D) PBMCs plus granulocytes exposed to 0–200 
nM TBT (donor F261). E) Granulocytes exposed to 0–200 nM TBT (donor F261). * 
Indicates a significant decrease in secretion and + indicates a significant increase in secretion 
compared to control cells (cells treated with vehicle alone).
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Effects of 24 h, 48 h and 6 day exposures to DBT on IL-6 secretion from highly purified 
human NK cells, monocyte-depleted PBMCs, PBMCs, PBMCs plus granulocytes, and 
granulocytes in individual donors. A) NK cells exposed to 0–5 µM DBT (donor KB169). B) 
Monocyte-depleted PBMCs exposed to 0–5 µM DBT (donor F152). C) PBMCs exposed to 
0–5 µM DBT (donor F285). D) PBMCs plus granulocytes exposed to 0–5 µM DBT (donor 
F285). E) Granulocytes exposed to 0–5 µM DBT (donor F285). * Indicates a significant 
decrease in secretion and + indicates a significant increase in secretion compared to control 
cells (cells treated with vehicle alone).
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Effects of TNFα and IL-1β on secretion of IL-6. A) Cells exposed to 10,000 and 1000 pg/ 
mL TNFα for 24 h. B) Cells exposed to 1000 and 100 pg/ mL IL-1β for 24 h. C) TNFα 
antibody (TAb), IL-1β antibody (IAb), and an isotype control antibody (CAb) were added to 
cells 1 h prior to exposure to 0.25 µM DBT for 24 h. Data are from representative 
experiment and results were repeated in cells from additional donors. + Indicates a 
significant increase in secretion compared to control cells (cells treated with vehicle alone).
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Table 3
Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from highly purified human NKs.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 4685±174 1618±31 12391±260 7374±250
2.5 5236±302 1375±109* 8175±78* 8893±785
5 4930±229 1141±31* 8138±263* 8004±688
10 4764±4 990±16* 7777±277* 8008±1380
25 4700±148 646±32* 6996±206* 5795±402*
50 4405±124 419±24* 5052±97* 4393±278*
100 2935±89* ND* 135±42* 170±63*
200 84±241* ND* ND* ND*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 4424±92 2139±61 16394±501 24580±941
2.5 4616±982 3934±204+ 13359±88* 23221±1332
5 3991±464 3635±611+ 12967±466* 20260±589*
10 3745±260* 1092±136 12166±341 23077±201*
25 3527±190* 1199±128* 9540±156* 11293±437*
50 3682±329* 1438±108* 6342±149* 345±34*
100 2432±63* 45±64* 1201±56* ND*
200 29±10* 357±171* 96±44* ND*
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM KB166 KB167 KB168 KB169
0 4030±200 1635±35 15482±575 13027±592
2.5 8341±396+ 2194±140+ 1710±132* 12893±1138*
5 7310±138+ 3036±177+ 14510±2402 10243±509*
10 8299±179+ 1541±201 19291±920+ 9154±516*
25 4780±17+ 2160±65+ 8625±231* 8232±1225*
50 3791±63 672±82* 1920±99* 5871±269*
100 3291±76* ND* 1710±33* 477±33*
200 ND* ND* 15463±297 ND*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion and
+
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05 ND = not detectable.
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Table 4
Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from monocyte-depleted PBMCs.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F137 F142 F145 F156
0 1495±113 64607±3102 8647±309 36151±711
2.5 1171±57* 39411±9167* 6675±42* 42362±2282+
5 1105±72* 38274±8450* 6763±474* 39758±2410
10 1072±49* 47239±4826* 6814±164* 45813±1123+
25 1011±70* 55389±2496* 6689±508* 39288±1090+
50 809±57* 45285±2781* 5680±313* 41484±1238+
100 758±86* 47883±1614* 4897±157* 40276±777+
200 241±168* 2285±72* ND* 6958±796*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F137 F142 F145 F156
0 7059±349 94610±2681 11822±509 56627±1086
2.5 9471±661+ 96509±397 7847±87* 54410±1896
5 6646±447 82913±2441* 6827±205* 67550±3147+
10 7533±1649 80267±3758* 7673±615* 51100±1749*
25 6844±506 77903±424* 7021±201* 55759±2608
50 6386±239 72954±2077* 7026±46* 71502±6127+
100 3567±436* 68994±1794* 7200±313* 53157±7680
200 ND* 3337±455* ND* 11518±501*
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F137 F142 F145 F156
0 223±6 46608±1494 9920±489 20362±315
2.5 165±17* 57987±1806+ 8187±347* 22137±1585
5 116±23* 59399±7568 7781±305* 21855±1738
10 102±8* 57118±493+ 6417±445* 25086±288+
25 106±17* 57137±272+ 7035±200* 22047±361+
50 84±3* 55719±981+ 6472±421* 24310±479+
100 32±11* 49993±753+ 4787±248* 19560±792
200 ND* 6379±131* ND* 2515±240*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion and
+
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05 ND = not detectable.
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Table 5
a. Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from PBMCs.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 107735±4735 123182±4413 108921±458 46005±308
2.5 119503±1019+ 157545±2460+ 156436±1916+ 109857±1151+
5 106508±3257 160273±656+ 130376±688+ 90252±1561+
10 89450±4474* 158333±1001+ 102073±6556 80770±2100+
25 1365±220* 150697±105+ 119042±2900+ 86894±964+
50 100201±8444 172636±10351+ 106618±315* 83240±4790+
100 12540±1176* 120030±1211 55527±793* 90844±901+
200 1386±477* ND* ND* ND*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 86054±3721 159936±402 189796±3587 141±370
2.5 112033±8360+ 177617±1486+ 118288±5352* 104303±210+
5 112825±3112+ 199994±2634+ 200393±321+ 98768±3031+
10 114158±1589+ 198545±1328+ 192884±1895 94040±1152+
25 79846±6771 219299±7449+ 211481±5805+ 99091±1283+
50 10596±1016+ 233965±1424+ 205656±8477 159333±1266+
100 ND* 155183±1086+ 98358±3466* 147333±1748+
200 ND* 2371±822* ND* 52990±573+
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 143040±5912 164368±443 170226±2050 66006±1860
2.5 124754±5201* 182069±2296+ 165820±2790 77252±1936+
5 131230±4148* 149609±939* 199386±1616+ 81020±2811+
10 150126±4018 197011±2704+ 170226±11833 107049±1158+
25 156564±12441 212598±522+ 172835±9901 97831±611+
50 150583±1126 217287±1795+ 173241±8388 131513±1254+
100 94735±5760* 154345±1202* 38864±2611* 228035±1313+
200 2011±695* 7816±80* ND* 11223±100*
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b. Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from PBMCs plus Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 24852±1323 37539±1932 26205±352 3124±3
2.5 30787±1395+ 44261±1248+ 18660±906* 3107±16
5 38369±748+ 46178±1355+ 24221±203* 3317±22+
10 37506±157+ 55233±1673+ 26693±593 3155±17
25 47101±460+ 59678±966+ 24774±982 3191±36
50 48068±1024+ 66622±3007+ 26985±1150 3514±69+
100 68199±958+ 77344±2115+ 40481±2245+ 4951±47+
200 20591±432* 22733±300* 29652±1043+ 4079±18+
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 8475±122 17469±302 3058±96 1085±18
2.5 9798±245+ 23335±325+ 3991±109+ 1112±28
5 13232±1047+ 24021±1180+ 3800±15+ 1183±30+
10 10586±367+ 35240±198+ 3823±81+ 1216±7+
25 17818±316+ 23488±540+ 3980±122+ 1385±45+
50 17101±364+ 42078±994+ 4429±48+ 1642±40+
100 28636±786+ 52935±293+ 4577±166+ 3264±32+
200 8182±121* 15926±198* 2188±62* 2387±5+
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 280±34 1063±21 13±0 86±3
2.5 219±4 1080±187 16±1+ 345±23+
5 375±14+ 1159±7+ 16±2 94±12
10 278±51 1782±18+ 26±0+ 64±5*
25 531±4+ 2380±7+ 30±0+ 117±12+
50 924±27+ 3718±15+ 35±2+ 650±3+
100 3318±51+ 7225±28+ 97±2+ 1581±31+
200 355±37 429±37* 65±2+ 347±16+
c. Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 122±2 137±11 785±53 137±13
2.5 882± 41+ 507±3+ 1214±11+ 460±9+













Brown et al. Page 28
c. Effects of 24 h, 48 h, 6 day exposures to TBT on IL-6 secretion from Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
5 1044±13+ 300±5+ 1238±42+ 326±25+
10 963±30+ 313±20+ 1515±25+ 309±23+
25 315±20+ 219±34+ 948±10+ 209±2+
50 299±35+ 161±1 1304±21+ 516±19+
100 229±23+ 162±6+ 1306±17+ 339±16+
200 ND* ND* 206±22* ND*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 6±6 110±15 87±14 1292±25
2.5 733±20+ 949±12+ 382±0+ 1329±38
5 1635±15+ 885±35+ 305±27+ 1428±42+
10 1380±15+ 1260±12+ 297±13+ 1474±9+
25 365±6+ 1110±51+ 201±8+ 1710±62+
50 394±19+ 635±25+ 203±2+ 2068±55+
100 274±5+ 163±13+ 80±8* 4328±45+
200 ND* ND* ND* 3106±6+
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[TBT] nM F252 F257 F261 F264
0 9±0 5±1 6±1 4±1
2.5 25±1+ 48±1+ 29±1+ 14±+
5 22±1+ 53±1+ 9±2 7±1+
10 12±1+ 18±1+ 9±1+ 9±2+
25 10±0+ 8±0+ 8±1 8±1+
50 10±1 9±1+ 7±2 8±1+
100 9±1 8±1+ 10±1+ 6±1
200 8±0* 4±0 8±1+ 4±1
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion and
+
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05 ND = not detectable.
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Table 6
Effects of 24 h, 48 h, 6 day exposures to DBT on IL-6 secretion from highly purified human NKs.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM KB130 KB155 KB169
0 8077±166 3220±118 10146±309
0.05 9055±322+ 3867±286+ 9124±267*
0.1 7864±480 3973±210+ 9234±196*
0.25 4963±596* 3811±216+ 6985±209*
0.5 ND* 1569±139* 2155±103*
1 ND* 63±0* 66±5*
2.5 ND* ND* ND*
5 ND* ND* ND*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM KB130 KB155 KB169
0 8422±204 10064±680 7338±72
0.05 12286±1696+ 11037±510 871±518*
0.1 9106±218+ 10011±245 8203±377+
0.25 6710±136* 8517±759* 8768±9*
0.5 1467±83* 2908±100* 3754±206*
1 719±97* 544±71* 318±24*
2.5 629±87* ND* 36±14*
5 764±68* ND* 28±8*
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM KB130 KB155 KB169
0 8834±530 13743±209 24580±941
0.05 8161±1807 11926±877 23221±1332
0.1 7559±908 12697±904 20260±589*
0.25 5030±30* 10789±538* 23077±201
0.5 416±119* 2697±199* 11293±437*
1 ND* ND* 345±34*
2.5 ND* ND* ND*
5 ND* ND* ND*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion and
+
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05 ND = not detectable.
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Table 8
a. Effects of 24 h, 48 h, 6 day exposures to DBT on IL-6 secretion from PBMCs.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 34255±142 14998±986 32382±357 95826±2410
0.05 63720±1078+ 61442±2081+ 92678±862+ 112870±348+
0.1 60002±523+ 65886±1367+ 53085±3654+ 118145±724+
0.25 76453±765+ 69788±4877+ 63289±641+ 119362±362+
0.5 68152±745+ 53195±3027+ 61937±861+ 61681±3093*
1 14593±438* 16405±1398 13622±735* 17275±703*
2.5 ND* ND* ND* ND*
5 ND* ND* ND* ND*
48 h Interleukin 6 secreted in ng/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 42735±177 53716±1836 30850±33 97222±962
0.05 61846±122+ 76212±1266+ 45764±344+ 148278±631+
0.1 70898±912+ 87289±884+ 43992±772+ 157389±1549+
0.25 88325±798+ 108349±711+ 63154±343+ 124000±2333+
0.5 91577±266+ 91289±1299+ 52811±348+ 83444±1678*
1 15717±1110* 49716±872* 27078±788* 23944±1798*
2.5 ND* ND* 50±216* ND*
5 ND* ND* ND* ND*
6 day Interleukin 6 secreted in ng/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 3922±9 11020±543 35576±77 115832±599
0.05 14426±4+ 18824±471+ 50986±239+ 152672±2344+
0.1 19597±8+ 24039±245+ 58209±77+ 168474±3388+
0.25 41418±6+ 37294±1387+ 46682±674+ 139042±905+
0.5 32052±1+ 42980±1682+ 30716±1216* 89264±1864*
1 ND* 15294±204+ 7323±155* 21314±226*
2.5 ND* ND* 116±51* ND*
5 ND* ND* ND* ND*
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b. Effects of 24 h, 48 h, 6 day exposures to DBT on IL-6 secretion from PBMCs plus Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 8587±89 8593±60 12411±381 15883±675
0.05 8138±302* 10178±136+ 15173±84+ 18437±737+
0.1 12487±328+ 9162±324 14586±300+ 18727±658+
0.25 16162±363+ 11058±195+ 14788±307+ 20621±407+
0.5 17618±430+ 10477±130+ 15558±28+ 21298±388+
1 9364±102+ 7475±34* 7244±146* 17080±404
2.5 265±25* 520±17* 0±18* 2804±60*
5 ND* ND* ND* 267±92*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 5797±38 6346±13 11944±111 11795±238
0.05 6270±58+ 9284±64+ 15322±317+ 13838±531+
0.1 6792±88+ 7465±315+ 14925±466+ 15217±419+
0.25 9783±17+ 11645±78+ 17219±17+ 19809±226+
0.5 10257±307+ 11280±107+ 15552±110+ 20011±851+
1 7253±34+ 9277±30+ 8777±93* 16104±2294
2.5 394±11* 95±16* ND* 1150±264*
5 215±45* ND* ND* ND*
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 21±10 30±10 1843±18 49±4
0.05 161±4+ 498±12+ 1845±49 348±244
0.1 159±13+ 531±9+ 1991±36 656±166+
0.25 359±15+ 260±6+ 2699±16+ 456±37+
0.5 550±15+ 316±18+ 2638±22+ 321±26+
1 99±10+ 108±5+ 1020±35* 107±8+
2.5 ND* ND* ND* 37±5*
5 ND* ND* ND* 26±54
c. Effects of 24 h, 48 h, 6 day exposures to DBT on IL-6 secretion from Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 54±2 46±2 16±1 148±0
0.05 89±4+ 71±10+ 16±4 197±8+
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c. Effects of 24 h, 48 h, 6 day exposures to DBT on IL-6 secretion from Granulocytes.
24 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0.1 72±3+ 65±8+ 10±1* 254±9+
0.25 92±2+ 93±25 17±3 22±1*
0.5 79±1+ 65±2+ 1±2* 252±3+
1 19±1* 15±1* 0±1* 162±4+
2.5 ND* ND* ND* 17±0*
5 ND* ND* ND* 8±0*
48 h Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 35±10 58±2 36±1 149±4
0.05 34±3 57±9 34±0* 143±1
0.1 33±5 59±4 31±2* 136±2*
0.25 44±3+ 78±6+ 45±3+ 221±8+
0.5 32±1* 70±7 30±3* 231±3+
1 5±2* 20±0* 6±1* 131±9*
2.5 ND* ND* ND* ND*
5 ND* ND* ND* ND*
6 day Interleukin 6 secreted in pg/mL (mean±S.D.)
[DBT] µM F285 F290 F294 F299
0 ND 6±0 ND 4±0
0.05 ND 22±1+ ND 9±1+
0.1 ND 23±4+ ND 5±1
0.25 ND 18±4+ ND 6±1
0.5 ND 10±3 ND 4±0
1 14±2+ 7±3 ND 7±1
2.5 ND 4±2 ND 7±1+
5 ND ND* ND 6±1+
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion and
+
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05 ND = not detectable.
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